Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.

Therapeutic drug monitoring - 1 Oct 2006

Lin Ying-Chi, Ellingrod Vicki L, Bishop Jeffrey R, Miller Del D

Abstract excerpt

P-glycoprotein (PGP) is a polymorphic efflux transporter located on the blood brain barrier that potentially affects the penetration of atypical antipsychotics into the central nervous system. Increased antipsychotic penetration to the primary site of activity may result in greater symptom improv...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antipsychotic Agents
Share to ATP Binding Cassette Transporter, Subfamily B, Member 1
Share to Benzodiazepines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Olanzapine

Share to Pharmacogenetics

Share to Polymorphism, Genetic

Share to Schizophrenia

Share to Weight Gain

Source

Identifiers

PMID: 17038883
DOI: 10.1097/01.ftd.0000246761.82377.a6

Genes

PGP

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17038883-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relationship between P-glycoprotein (PGP) polymorphisms and response to olanzapine treatment in schizophrenia.PMID 17038883Read ↗

Polymorphisms influencing olanzapine metabolism and adverse effects in healthy subjects.Semantic proximity Read ↗

Metabolic, genetic, and pharmacokinetic parameters for the prediction of olanzapine efficacy.Semantic proximity Read ↗

Impact of polymorphisms in transporter and metabolizing enzyme genes on olanzapine pharmacokinetics and safety in healthy volunteers.Semantic proximity Read ↗

The pharmacogenetics of treatment with olanzapineSemantic proximity Read ↗

Effect of ABCB1 C3435T Polymorphism on Pharmacokinetics of Antipsychotics and Antidepressants.Semantic proximity Read ↗

Catechol-O-methyltransferase rs4680 and rs4818 haplotype association with treatment response to olanzapine in patients with schizophrenia.Semantic proximity Read ↗

Genetic variation in CYP3A43 is associated with response to antipsychotic medication.Semantic proximity Read ↗

Olanzapine metabolism and the significance of UGT1A448V and UGT2B1067Y variants.Semantic proximity Read ↗

Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia.Semantic proximity Read ↗

Associations between MDR1 gene polymorphisms and schizophrenia and therapeutic response to olanzapine in female schizophrenic patients.Semantic proximity Read ↗

Differing response to antipsychotic therapy in schizophrenia: pharmacogenomic aspectsSemantic proximity Read ↗

Genetic Predictors of Antipsychotic Efflux Impairment via Blood-Brain Barrier: Role of Transport ProteinsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.